Hookipa Pharma inc (HOOK) - News Archive

New York and Vienna, Austria: Insights into Hookipa Pharma s Strategic Movements and Market RegulationsFOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDIC...

Understanding Hookipa Pharma: Implications of Recent U.K. Disclosure Requirements and Market RegulationsAs the pharmaceutical landscape continues to evolve, companies must navigate complex regulatory frameworks, particu...

In a recent press release dated January 7, 2025, HOOKIPA Pharma Inc. (NASDAQ: HOOK) informed shareholders about important updates regarding U.K. disclosure requirements. As a clinical-stage biopharmaceutical company spe...

The Landscape of Pharmaceutical Innovation: An Important Update on Poolbeg Pharma plc and HOOKIPA Pharma Inc.In the fast-paced world of biopharmaceuticals, strategic partnerships and potential mergers can significantly...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.Innovative Pathways...

HOOKIPA Pharma Poised to Make Waves with Preclinical Data Presentation at RAS Industry SummitNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTI...

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is scheduled to unveil a comprehensive preclinical proof-of-concept package for its investigational drug HB-700 at the upcoming Industry Summit on RAS, slated for September 24-26, 2024...

Hookipa Pharma Implements Reverse Stock Split to Improve Share ValueOn July 9, 2024, HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA) will undergo a 1-for-10 reverse stock split of its outstanding shares of common stock, as...

Combining the articles:HOOKIPA Pharma Inc. made an electrifying announcement today, revealing that the first person has been dosed in a Phase 1b clinical trial for HB-500. This groundbreaking investigational therapeutic...

CSIMarket.com - May 23, 2024HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a biopharmaceutical company focused on developing immunotherapeutics based on its innovative arenavirus platform, recently released updated positi...

HOOKIPA Pharma Inc, a leader in the development of a novel class of immunotherapeutics derived from its proprietary arenavirus platform, recently unveiled the final pivotal design of its Phase 2/3 trial investigating th...

HOOKIPA Pharma Grants Inducement Award to Chief Development Officer Mark WinderlichThe Compensation Committee of HOOKIPA Pharma Inc. has approved the grant of non-statutory options to Mark Winderlich, the newly appointe...

HOOKIPA Pharma Inc., a pioneer in biopharmaceutical immunotherapeutics based on its innovative arenavirus platform, has declared two decisive areas of focus for its resources, with high hopes to make significant strides...

In a recent press release, HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA) has announced that it has secured a significant financial boost from Gilead Sciences (Gilead). With the purchase of 15 million shares at $1.4167 per...

HOOKIPA Pharma Inc., a renowned biopharmaceutical company known for its innovative immunotherapeutics, has recently announced a significant breakthrough - the clearance of its Investigational New Drug (IND) application...